spacer
home > white papers > Tightening Your Supply Chain Against Counterfeits - World Courier
WHITE PAPERS
logo_World_Cour5.JPEG

World Courier

phone +44 (0)20 7928 7256
email marketing@worldcourier.com
web http://www.worldcourier.com
email 12th Floor, 25 Farringdon Street, London, EC4A4AB

Tightening Your Supply Chain Against Counterfeits

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters.

While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link.

How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Automated Dried Spot Sampling and Analysis System Redefines Workflow

The Thermo Scientific Transcend DSX-1 integrated sample prep and ultra-high-performance liquid chromatography (UHPLC) system delivers high throughput, sensitive and compliant analysis
More info >>


White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement